Granted Patent: Diazene-bridged crown ether lithium compounds and methods for their use

File Download
  • No File Attached
Patent History
  • Application
    GB20070014337
    2005-12-22
  • Granted
    GB 2437456
    2009-11-11
Supplementary

  • Basic View
  • Metadata View
  • XML View
TitleDiazene-bridged crown ether lithium compounds and methods for their use
Granted PatentGB 2437456
Granted Date2009-11-11
Priority Date2005-12-22 PCT/CN2005002282
2004-12-22 US 11/638100P
InventorsCHIMING CHE,
KWOKFAI SO,
HIUTUNG IONA SHAM,
PAUL MICHEL GEORGES VANHOUTTE
AbstractThis invention provides a method for treating an eye disease in a patient comprising: providing a photosensitive prodrug that releases upon exposure to light an active ingredient to treat the eye disease; administering the prodrug in a pharmaceutically accepted vehicle to the subject, and exposing the eye of the subject to an external light source to cause the prodrug to release the active ingredient. This invention also provides a composition for the treatment of glaucoma, comprising a compound containing a lithium ion-chelated in a crown ether- or aza-crown ether-containing chromene or diazene derivative and a pharmaceutically acceptable carrier.
ReferencesJP 6116280 (A) 1994-04-26

US 5132436 (A) 1992-07-21

US 5705689 (A) 1998-01-06
DC Field
Value
dc.contributor.inventorCHIMING CHE,
dc.contributor.inventorKWOKFAI SO,
dc.contributor.inventorHIUTUNG IONA SHAM,
dc.contributor.inventorPAUL MICHEL GEORGES VANHOUTTE
dc.date.accessioned2011-10-19T06:39:51Z
patents.date.application2005-12-22
dc.date.available2011-10-19T06:39:51Z
patents.date.granted2009-11-11
patents.date.priority2005-12-22 PCT/CN2005002282
patents.date.priority2004-12-22 US 11/638100P
dc.description.abstractThis invention provides a method for treating an eye disease in a patient comprising: providing a photosensitive prodrug that releases upon exposure to light an active ingredient to treat the eye disease; administering the prodrug in a pharmaceutically accepted vehicle to the subject, and exposing the eye of the subject to an external light source to cause the prodrug to release the active ingredient. This invention also provides a composition for the treatment of glaucoma, comprising a compound containing a lithium ion-chelated in a crown ether- or aza-crown ether-containing chromene or diazene derivative and a pharmaceutically acceptable carrier.
patents.description.assigneeVANHOUTTE PAUL MICHEL GEORGES [CN]; CHE CHIMING [HK]; SO KWOKFAI [CN]; SHAM HIUTUNG IONA [CN]; UNIV HONG KONG [HK]
patents.description.ccGB
patents.description.countryUnited Kingdom
patents.description.kindB
patents.identifier.applicationGB20070014337
patents.identifier.grantedGB 2437456
patents.identifier.hkutechidChm-2004-00168
dc.identifier.urihttp://hdl.handle.net/10722/142243
patents.relation.familyCN 101115489 (A) 2008-01-30
patents.relation.familyDE 112005003183 (T5) 2007-11-08
patents.relation.familyJP 2008524268 (A) 2008-07-10
patents.relation.familyUS 2007298127 (A1) 2007-12-27
patents.relation.familyUS 7468434 (B2) 2008-12-23
patents.relation.familyWO 2006066511 (A1) 2006-06-29
dc.relation.referencesJP 6116280 (A) 1994-04-26
dc.relation.referencesUS 5132436 (A) 1992-07-21
dc.relation.referencesUS 5705689 (A) 1998-01-06
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License For Public Patent Documents
dc.titleDiazene-bridged crown ether lithium compounds and methods for their use
dc.typePatent
patents.typePatent_granted